Mark Mallon wraps a short stint as CEO of Ironwood, jumping out to pursue 'multiple passions' in the wake of setbacks
Mark Mallon built his career over a 24-year stretch at AstraZeneca. But he managed less than 2 years as CEO of Ironwood.
Ironwood announced Monday afternoon that Mallon is stepping down, quoting him as enthused about the chance to satisfy “multiple passions” as he headed off in pursuit of a new leadership post. The biotech’s stock was up 13% ahead of the bell Tuesday.
President Tom McCourt was bumped to the interim CEO role during the recruitment phase for the next CEO and the board chair, Julie McHugh, will help steer the company as executive chairman.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,000+ biopharma pros reading Endpoints daily — and it's free.